Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (201-210 of 487) with videos related to

Pageof 49
Sort By:
Pharmacoeconomics|October 27, 2023
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology AssessmentsAlex J Turner, Cormac Sammon, Nick Latimer, et al.
Current Problems in Cancer|October 17, 2021
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implicationsRoberto Carmagnani Pestana, Jason Roszik, Roman Groisberg, et al.
Clinical Genitourinary Cancer|December 20, 2015
Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic CorrelatesAbhishek Maiti, Robert E Brown, Paul G Corn, et al.
Cancers|October 23, 2021
Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue SarcomaJason Roszik, Lisa Maria Mustachio, John A Livingston, et al.
JCO Precision Oncology|February 20, 2026
Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid CarcinomaSarah Hamidi, Vivek Subbiah, Maria E Cabanillas, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|July 3, 2014
Incidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodesVeerasathpurush Allareddy, Satheesh Elangovan, Steven L Fletcher, et al.
Plos One|April 16, 2011
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signaturesVivek Subbiah, Aung Naing, Robert E Brown, et al.
Nature Communications|June 17, 2022
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
JAMA Network Open|May 25, 2022
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung CancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Diagnostics (Basel, Switzerland)|February 29, 2020
Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot StudyKalevi Kairemo, Elmer B Santos, Homer A Macapinlac, et al.
Pageof 49

Showing results (201-210 of 487) with videos related to

Sort By:
Pageof 49
Pharmacoeconomics|October 27, 2023
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology AssessmentsAlex J Turner, Cormac Sammon, Nick Latimer, et al.
Current Problems in Cancer|October 17, 2021
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implicationsRoberto Carmagnani Pestana, Jason Roszik, Roman Groisberg, et al.
Clinical Genitourinary Cancer|December 20, 2015
Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic CorrelatesAbhishek Maiti, Robert E Brown, Paul G Corn, et al.
Cancers|October 23, 2021
Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue SarcomaJason Roszik, Lisa Maria Mustachio, John A Livingston, et al.
JCO Precision Oncology|February 20, 2026
Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid CarcinomaSarah Hamidi, Vivek Subbiah, Maria E Cabanillas, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|July 3, 2014
Incidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodesVeerasathpurush Allareddy, Satheesh Elangovan, Steven L Fletcher, et al.
Plos One|April 16, 2011
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signaturesVivek Subbiah, Aung Naing, Robert E Brown, et al.
Nature Communications|June 17, 2022
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
JAMA Network Open|May 25, 2022
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung CancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Diagnostics (Basel, Switzerland)|February 29, 2020
Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (<sup>18</sup>F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot StudyKalevi Kairemo, Elmer B Santos, Homer A Macapinlac, et al.
Pageof 49